XTNT Stock Overview
Provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Xtant Medical Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.38 |
| 52 Week High | US$0.99 |
| 52 Week Low | US$0.33 |
| Beta | -0.042 |
| 1 Month Change | -17.32% |
| 3 Month Change | -18.42% |
| 1 Year Change | -59.06% |
| 3 Year Change | -42.27% |
| 5 Year Change | -46.10% |
| Change since IPO | -99.91% |
Recent News & Updates
Shareholder Returns
| XTNT | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -18.9% | -9.5% | -12.1% |
| 1Y | -59.1% | -6.3% | -5.8% |
Return vs Industry: XTNT underperformed the US Medical Equipment industry which returned -3.2% over the past year.
Return vs Market: XTNT underperformed the US Market which returned -3.8% over the past year.
Price Volatility
| XTNT volatility | |
|---|---|
| XTNT Average Weekly Movement | 13.6% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.7% |
Stable Share Price: XTNT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: XTNT's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 225 | Sean Browne | xtantmedical.com |
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. The company offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, which can be compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also provides sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications.
Xtant Medical Holdings, Inc. Fundamentals Summary
| XTNT fundamental statistics | |
|---|---|
| Market cap | US$63.27m |
| Earnings (TTM) | -US$16.45m |
| Revenue (TTM) | US$117.27m |
0.5x
P/S Ratio-3.2x
P/E RatioIs XTNT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XTNT income statement (TTM) | |
|---|---|
| Revenue | US$117.27m |
| Cost of Revenue | US$49.05m |
| Gross Profit | US$68.22m |
| Other Expenses | US$84.67m |
| Earnings | -US$16.45m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.12 |
| Gross Margin | 58.17% |
| Net Profit Margin | -14.03% |
| Debt/Equity Ratio | 79.5% |
How did XTNT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/08 06:56 |
| End of Day Share Price | 2025/04/08 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Xtant Medical Holdings, Inc. is covered by 12 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Wittes | Brean Capital |
| Michael Gorman | BTIG |
| null null | CG Capital |